AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) is set to announce its third-quarter 2022 financial results on October 28, 2022, before market opening. A live webcast of the earnings call will occur at 8 a.m. CT, accessible through AbbVie's Investor Relations website. An archived version will be available later the same day. AbbVie aims to deliver innovative medicines across various therapeutic areas, addressing serious health issues, including immunology, oncology, and more. For further details, visit the company's official website.
AbbVie (NYSE: ABBV) presented new data from studies on risankizumab (SKYRIZI) and upadacitinib (RINVOQ) during the United European Gastroenterology (UEG) Week 2022. Key highlights include final analyses from the U-ACHIEVE study, which evaluated RINVOQ's efficacy in treating moderately to severely active ulcerative colitis, and the U-EXCEL study focusing on Crohn's disease. A total of 17 abstracts, featuring oral presentations and e-posters, showcase AbbVie's commitment to advancing treatments for inflammatory bowel disease. The investigational use of these medications in Crohn's disease in the EU is noted.
AbbVie’s Allergan Aesthetics and skinbetter science launched the Forces of Beauty report on Sept. 22, 2022, under the DREAM Initiative. The report explores racial representation in beauty standards, revealing that only 17% of women feel their racial beauty is accepted. Key findings show 1 in 4 women of color perceive beauty standards as racist. In tandem, a new royalty-free image gallery, resulting from a partnership with Shutterstock Studios, aims to promote diverse representations across various demographics. The initiative seeks to foster dialogue and education around inclusive beauty.
AbbVie (NYSE: ABBV) received a positive opinion from the EMA's CHMP for risankizumab (SKYRIZI®) to treat adults with moderately to severely active Crohn's disease. The recommendation stems from three Phase 3 studies showing significant improvements in clinical remission and endoscopic response at 12 weeks post-treatment. If approved, this would be the first specific IL-23 inhibitor available for Crohn's disease in the EU. A final European Commission decision is expected in Q4 2022, marking the third indication for risankizumab in the region.
AbbVie announced it will present findings from the Phase 3 M15-736 trial and data on BOTOX at the 2022 MDS International Congress in Madrid from September 15-18. Key presentations include results on the continuous infusion of ABBV-951 for advanced Parkinson's disease and real-world efficacy of BOTOX for spasticity and cervical dystonia. AbbVie emphasizes its commitment to addressing the needs of patients with movement disorders, reinforcing its leadership in neuroscience.
AbbVie has opened public voting for its 30th annual Cystic Fibrosis (CF) Scholarship program, running until September 28. This year, 40 students living with CF are competing for two $25,000 scholarships based on academic excellence and community involvement. Earlier in 2022, AbbVie awarded $3,000 to 40 CF students, totaling over $3.7 million in scholarships since the program's inception. The winners will be announced in early November, highlighting AbbVie's commitment to supporting the CF community.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced the selection of 25 real patients for its new BOTOX® Cosmetic 'See Yourself' campaign after receiving nearly 20,000 submissions. The campaign aims to showcase authentic testimonials and experiences, reflecting the emotional and physical impact of BOTOX® treatments. The latest content includes interviews, treatment diaries, and informative sessions addressing common patient inquiries. BOTOX® Cosmetic remains the leading product in its category, approved by the FDA for treating facial lines.
AbbVie announced 100-week results from KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI (risankizumab) in adults with active psoriatic arthritis. Over 50% of patients achieved a 90% reduction in psoriasis severity (PASI 90), with similar joint symptom improvement (ACR20) as at week 52. The treatment maintained long-term efficacy, with no new safety signals observed. Serious treatment-emergent adverse events were low, with a rate of 7.6 E/100PY in KEEPsAKE 1. These findings were presented at the 31st EADV Congress, highlighting SKYRIZI's potential as a long-term treatment option.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.41 per share, payable on November 15, 2022, to shareholders of record by October 14, 2022. Since its inception in 2013, AbbVie has increased its dividend by over 250%. The company is a member of the S&P Dividend Aristocrats Index, which includes firms that have consistently raised dividends for at least 25 consecutive years.
AbbVie's MEASURE-AD study, spanning three years and 28 countries, highlights the significant clinical, psychosocial, and economic burdens faced by patients with moderate to severe atopic dermatitis, particularly those not on systemic therapy. Results presented at the EADV Congress indicate that these patients experience higher disease severity scores and lower quality of life, emphasizing the need for improved treatment options. The analysis shows that only half of eligible patients receive systemic therapy, revealing potential undertreatment in this population.